Kidney Disease

 

= ILF Board Member Author(s)

FATTY KIDNEY DISEASE: A NEW RENAL AND ENDOCRINE CLINICAL ENTITY? DESCRIBING THE ROLE OF THE KIDNEY IN OBESITY, METABOLIC SYNDROME, AND TYPE 2 DIABETES.

High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post–myocardial infarction patients

Cardiovascular and Renal Outcomes in an Excellent Chronic Kidney Disease Clinic Compared

with an Outpatient Clinic in a Primary Care Setting: A Retrospective Cohort Study.

Carotid Intima-Media Thickness: A Surrogate Marker for Cardiovascular Disease in Chronic

Kidney Disease Patients.

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With Diabetes.

Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL–ED): A Multicenter, Prospective, Observational Study

Association Between Plasma Concentration of Klotho Protein, Osteocalcin, Leptin, Adiponectin, and Bone Mineral Density in Patients with Chronic Kidney Disease

Novel finding of caveolin-2 in apical membranes of proximal tubule and first detection of caveolin-2 in urine: A promising biomarker of renal disease.

Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations.

Personalized medicine in diabetic kidney disease: a novel approach to improve trial design and patient outcomes

Medication Regimen Complexity and Hospital Readmission in Older Adults With Chronic Kidney Disease.

Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?

Clinical application of polysialylated therapeutic proteins.

Falls and Fall-Related Injuries Among US Adults Aged 65 or Older With Chronic Kidney Disease.

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease

ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?

Effects of statin therapy on chronic kidney disease patients with coronary artery disease

High Neutrophil-to-Lymphocyte Ratio is a Significant Predictor of Cardiovascular and All-Cause Mortality in Patients Undergoing Peritoneal Dialysis.

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.

Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism.

Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease.

Impairment of PPARα and the Fatty Acid Oxidation Pathway Aggravates Renal Fibrosis during Aging.

The Main Determinants of Serum Resistin Level in Type 2 Diabetic Patients are Renal Function and Inflammation not Presence of Microvascular Complication, Obesity and Insulin Resistance.

Primary Prevention of Stroke in Chronic Kidney Disease Patients: A Scientific Update.

Renal artery stenting for atherosclerotic renal artery stenosis identified in patients with coronary artery disease: Does captopril renal scintigraphy predict outcomes?

End-stage renal disease treatment options education: What matters most to patients and families.

Renal PGC1α May Be Associated with Recovery after Delayed Graft Function.

How does CKD affect HbA1c?

What we do and do not know about women and kidney diseases; Questions unanswered and answers unquestioned: Reflection on World Kidney Day and International Woman's Day.